Download MendeleyMycobacterium tuberculosis CitA activity is modulated by cysteine oxidation and pyruvate binding.
Pathirage, R., Favrot, L., Petit, C., Yamsek, M., Singh, S., Mallareddy, J.R., Rana, S., Natarajan, A., Ronning, D.R.(2023) RSC Med Chem 14: 921-933
- PubMed: 37252106 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1039/d3md00058c
- Primary Citation Related Structures:
8GI7, 8GIW, 8GLB, 8GLL, 8GM9, 8GMF, 8GMI, 8GMK, 8S97, 8S9D - PubMed Abstract:
As an adaptation for survival during infection, Mycobacterium tuberculosis becomes dormant, reducing its metabolism and growth. Two types of citrate synthases have been identified in Mycobacterium tuberculosis , GltA2 and CitA. Previous work shows that overexpression of CitA, the secondary citrate synthase, stimulates the growth of Mycobacterium tuberculosis under hypoxic conditions without showing accumulation of triacylglycerols and makes mycobacteria more sensitive to antibiotics, suggesting that CitA may play a role as a metabolic switch during infection and may be an interesting TB drug target. To assess the druggability and possible mechanisms of targeting CitA with small-molecule compounds, the CitA crystal structure was solved to 2.1 Å by X-ray crystallography. The solved structure shows that CitA lacks an NADH binding site that would afford allosteric regulation, which is atypical of most citrate synthases. However, a pyruvate molecule is observed within the analogous domain, suggesting pyruvate may instead be the allosteric regulator for CitA. The R149 and R153 residues forming the charged portion of the pyruvate binding pocket were mutated to glutamate and methionine, respectively, to assess the effect of mutations on activity. Protein thermal shift assay shows thermal stabilization of CitA in the presence of pyruvate compared to the two CitA variants designed to decrease pyruvate affinity. Solved crystal structures of both variants show no significant structural changes. However, the catalytic efficiency of the R153M variant increases by 2.6-fold. Additionally, we show that covalent modification of C143 of CitA by Ebselen completely arrests enzyme activity. Similar inhibition is observed using two spirocyclic Michael acceptor containing compounds, which inhibit CitA with IC app 50 values of 6.6 and 10.9 μM. A crystal structure of CitA modified by Ebselen was solved, but significant structural changes were lacking. Considering that covalent modification of C143 inactivates CitA and the proximity of C143 to the pyruvate binding site, this suggests that structural and/or chemical changes in this sub-domain are responsible for regulating CitA enzymatic activity.
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center Omaha NE 68198 USA don.ronning@unmc.edu.
Organizational Affiliation:
